

**REMARKS**

Applicants respectfully request that the foregoing amendments to Claims 8-11, 15, 16-20 and 22 be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.

Respectfully submitted,

Date April 6, 2001

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

By *Philip J. Artiola* *Reg. No.*  
*38,819*  
for / Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

VERSION WITH MARKINGS TO SHOW CHANGES MADE

8. (Amended) Composition according to [one of Claims 4 to 7] claim 4, characterized in that the peptide has the R7V sequence.

9. (Amended) Composition according to [one of Claims 4 to 8] claim 4, characterized in that it comprises several peptides.

10. (Amended) Composition according to [one of Claims 4 to 9] claim 4, characterized in that the carrier system is chosen from albumins, KLH and MAP.

11. (Amended) Composition according to [one of Claims 4 to 10] claim 4, characterized in that it comprises, in addition, nonspecific immunity adjuvants.

15 (Amended) Composition according to [one of Claims 12 to 14] claim 12, characterized in that the DNA sequence is carried by an expression vector.

18. (Amended) Composition according to [one of Claims 15 to 17] claim 15, characterized in that the expression vector is a bacterial plasmid.

19. (Amended) Composition according to [one of Claims 15 to 18] claim 15, characterized in that the expression vector consists of all or part of a defective and/or nonpathogenic virus.

20. (Amended) Composition according to [one of Claims 1 to 19] claim 1, characterized in that the peptide is expressed in a host cell.

22. (Amended) Antibodies directed against a peptide used in one of the compositions according to [one of Claims 1 to 21] claim 1.